109047 ⎘
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; DNA or RNA fragments; Modified forms thereof General methods applicable to biologically active non-coding nucleic acids
CRISPR SYSTEM HIGH THROUGHPUT DIAGNOSTIC SYSTEMS AND METHODS
#1202COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES
#1203Compositions and methods for the delivery of nucleic acids
#1204PRODUCTION OF dsRNA IN PLANT CELLS FOR PEST PROTECTION VIA GENE SILENCING
#1205PROTEIN TRANSLATIONAL CONTROL
#1206COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1207Nucleic acids and methods for the treatment of Pompe disease
#1208ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME
#1209Oral delivery of antisense conjugates targeting PCSK9
#1210MODULATION OF EXPRESSION OF GENES RELATED TO T CELL EXHAUSTION
#1211Nanoparticle to target cancer
#1212SYNTHETIC NANOSTRUCTURES INCLUDING NUCLEIC ACIDS AND/OR OTHER ENTITIES
#1213IMAGING-BASED POOLED CRISPR SCREENING
#1214PROTEIN TRANSLATIONAL CONTROL
#1215RAAV-based compositions and methods
#1216POLYVALENT GUIDE RNAS FOR CRISPR ANTIVIRALS
#1217COMPOSITIONS AND METHODS FOR RAPID AND DYNAMIC FLUX CONTROL USING SYNTHETIC METABOLIC VALVES
#1218Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
#1219Nucleic acid-guided nucleases
#1220Polypeptide and nucleic acid capable of changing amylose content (AC) in plant, and use thereof
#1221RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#1222Compositions comprising chemically modified guide RNAs for CRISPR/Cas-mediated editing of HBB
#1223CHEMICALLY MODIFIED GUIDE RNAS FOR CRISPR/CAS-MEDIATED GENE CORRECTION
#1224Chemically modified guide RNAS for CRISPR/Cas-mediated gene regulation
#1225CRISPR editing to embed nucleic acid landing pads into genomes of live cells
#1226ATTENUATION OF BACTERIAL INFECTION
#1227NEUROGENESIS
#1228COMPOSITIONS AND METHODS FOR NUCLEOTIDE MODIFICATION-BASED DEPLETION
#1229METHOD FOR PRODUCING KNOCK-IN CELL
#1230VIRAL VECTORS FOR THE TREATMENT OF DIABETES
#1231SYNTHETIC SELF-REPLICATING RNA VECTORS ENCODING CRISPR PROTEINS AND USES THEREOF
#1232METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF CYP27A1
#1233Therapeutic Targets for Oncogenic KRAS-Dependent Cancers
#1234MODIFYING THE SPECIFICITY OF NON-CODING RNA MOLECULES FOR SILENCING GENES IN EUKARYOTIC CELLS
#1235METHODS AND COMPOSITIONS FOR CORRECTED ABERRANT SPLICE SITES
#1236OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1237Compositions and Methods for Treatment of Disorders Associated with Repetitive DNA
#1238CELL-PENETRATING PEPTIDES
#1239DIRECT OLIGONUCLEOTIDE SYNTHESIS ON CELLS AND BIOMOLECULES
#1240METHOD FOR IDENTIFYING FUNCTIONAL ELEMENTS
#1241AAV VECTOR-MEDIATED DELETION OF LARGE MUTATIONAL HOTSPOT FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
#1242COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#1243Genome editing system
#1244GENERATION OF CHIMERIC ANTIGEN RECEPTOR (CAR)-PRIMARY NK CELLS FOR CANCER IMMUNOTHERAPY USING A COMBINATION OF CAS9/RNP AND AAV VIRUSES
#1245Gene therapeutics for fibrodysplasia ossificans progressiva
#1246PROTEIN TRANSLATION USING CIRCULAR RNA AND APPLICATION THEREOF
#1247ENGINEERED EXOSOMES FOR TARGETED DELIVERY
#1248DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES WITH SHORTENED SENSE STRANDS
#1249CRISPR/CAS-BASED BASE EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION
#1250CRISPR/CAS9 GENE EDITING OF ATXN2 FOR THE TREATMENT OF SPINOCEREBELLAR ATAXIA TYPE 2
#1251HIGHLY MULTIPLEXED BASE EDITING
#1252CRISPR-associated (Cas) protein
#1253FUSION PROTEIN FOR ENHANCING GENE EDITING AND USE THEREOF
#1254MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
#1255Method for diagnosis of Alzheimer's disease using microrna
#1256IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#1257T:A TO A:T BASE EDITING THROUGH ADENOSINE METHYLATION
#1258GRP78 AND/OR HSP70 INHIBITORS FOR THERAPEUTIC USE
#1259CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN
#1260Applications of Streptococcus-derived Cas9 nucleases on minimal Adenine-rich PAM targets
#1261Modulatory polynucleotides
#1262Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1263ANTISENSE NUCLEIC ACIDS
#1264COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION
#1265METHODS AND COMPOSITIONS FOR MODULATING SPLICING OF ALTERNATIVE INTRONS
#1266OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
#1267Mammalian somatic cell with modified RNA encoding reprogramming factors
#1268METHODS, USES & COMPOSITIONS
#1269COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA
#1270OLIGONUCLEOTIDE-POLYMER MIKTOARM CONJUGATES AND METHODS OF USE
#1271Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
#1272NOVEL NUCLEIC ACID MODIFIERS
#1273COMPOSITIONS AND METHODS FOR IN VIVO EXCISION OF HIV-1 PROVIRAL DNA
#1274INCREASING GENOME STABILITY AND REPROGRAMMING EFFICIENCY OF INDUCED PLURIPOTENT STEM CELLS
#1275NEW ENGINEERED HIGH FIDELITY CAS9
#1276MICROGLIAL PROGENITORS FOR REGENERATION OF FUNCTIONAL MICROGLIA IN THE CENTRAL NERVOUS SYSTEM AND THERAPEUTICS USES THEREOF
#1277Oligonucleotides for inducing paternal UBE3A expression
#1278CANCER IMMUNOTHERAPY
#1279Polypeptide and nucleic acid capable of changing amylose content (ac) in plant, and use thereof
#1280CAS12a GUIDE RNA MOLECULES AND USES THEREOF
#1281MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER
#1282CTLA-4 aptamer conjugates
#1283COMPOSITIONS AND METHODS FOR GENE TARGETING USING CRISPR-CAS AND TRANSPOSONS
#1284RNA-TARGETING CAS ENZYMES
#1285Methods and compositions for increased double stranded RNA production
#1286SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE)
#1287LIGAND CLUSTERS AND METHODS OF THEIR USE AND PREPARATION
#1288Extracellular Vesicle Functionalization Using Oligonucleotide Tethers
#1289Engineered CRISPR-Cas9 nucleases with altered PAM specificity
#1290Methods of treating and diagnosing epilepsy
#1291COMPOSITIONS AND METHODS FOR MODULATING CGRP SIGNALING TO REGULATE INTESTINAL INNATE LYMPHOID CELLS
#1292A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER
#1293COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY
#1294METHOD FOR MULTIPLEX NUCLEIC ACID DETECTION BASED ON CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT
#1295Pathogen resistance in plants
#1296PLANT DNA METHYLTRANSFERASES AND USES THEREOF
#1297TREATMENT OF SYNUCLEINOPATHY AND ANIMAL MODELS OF SYNUCLEINOPATHY
#1298P-ETHOXY NUCLEIC ACIDS FOR IGF-1R INHIBITION
#1299CRISPR/RNA-GUIDED NUCLEASE-RELATED METHODS AND COMPOSITIONS FOR TREATING RHO-ASSOCIATED AUTOSOMAL-DOMINANT RETINITIS PIGMENTOSA (ADRP)
#1300Compositions and methods for organ specific delivery of nucleic acids
#1301COMPOSITION COMPRISING A MIXTURE OF DNA MOLECULES, USES THEREOF AS BIOLOGICAL INHIBITOR AND METHOD FOR PRODUCTION
#1302METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1303POLIOVIRUS RECEPTOR (PVR/CD155) KNOCKOUT CELLS DERIVED FROM RD (HUMAN RHABDOMYOSARCOMA) CELL LINE BY CRISPR
#1304Modulatory polynucleotides
#1305Safe harbor loci
#1306REVERSIR TM COMPOUNDS
#1307NOVEL CRISPR RNA TARGETING ENZYMES AND SYSTEMS AND USES THEREOF
#1308MATERIALS AND METHODS FOR BONE MARROW TRANSPLANTATION
#1309METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1310METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1311METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1312METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1313CRISPR enabled multiplexed genome engineering
#1314Therapeutic alteration of transplantable tissues through or exposure to RNA interference molecules
#1315EXOSOMES AND MICRO-RIBONUCLEIC ACIDS FOR TISSUE REGENERATION
#1316HIGH-EFFICACY CRISPRI SYSTEM AND STRONG SYNTHETIC PROMOTERS FOR ALPHAPROTEOBACTERIA AND GAMMAPROTEOBACTERIA
#1317CRISPR-cas9 SYSTEM AND USES THEREOF
#1318ANTISENSE OLIGOMERS AND USES THEREOF
#1319Long non-coding RNA gene expression signatures in disease monitoring and treatment
#1320METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1321Male sterile crop mutated on Ty-5 gene
#1322METHODS AND COMPOSITION FOR TRANSFERRING T-DNA INTO A PLANT
#1323IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA
#1324METHOD FOR SUPPRESSING PROTEIN TRANSLATION REACTION USING STAPLE NUCLEIC ACID
#1325ENGINEERED PROTEINS AND METHODS OF USE THEREOF
#1326COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAs AND METHODS OF USE
#1327Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes
#1328PARAVOVIRAL VECTORS AND METHODS OF MAKING AND USE THEREOF
#1329ENGINEERED DYSBIOSIS-SENSING PROBIOTIC FOR CLOSTRIDIUM DIFFICILE INFECTIONS AND RECURRING INFECTIONS MANAGEMENT
#1330CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY
#1331Multi-targeted single entity conjugates
#1332Compositions of DNA molecules, methods of making therefor, and methods of use thereof
#1333COMPOSITION FOR DELIVERY OF GENETIC MATERIAL
#1334NUCLEOBASE EDITORS HAVING REDUCED NON-TARGET DEAMINATION AND ASSAYS FOR CHARACTERIZING NUCLEOBASE EDITORS
#1335Liposomal Nanoparticle
#1336DETECTION METHOD FOR A TARGET NUCLEIC ACID AND KIT
#1337Novel tracrRNA system for Cas9
#1338CRISPR editing to embed nucleic acid landing pads into genomes of live cells
#1339GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
#1340Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1341Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1342NANOPARTICLE FOR DELIVERING RIBONUCLEOPROTEIN AND USE THEREOF
#1343CRISPR-BASED METHODS AND NOVEL COMPOSITIONS FOR TREATING VASCULAR DISORDERS
#1344SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
#1345METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1346Systems and methods for modulating CRISPR activity
#1347METHODS FOR APTAMER SELECTION
#1348Materials and methods for modifying and paratransformation of arthropods
#1349Compositions and methods for promoting homology directed repair
#1350CELL ENGINEERING USING RNAs
#1351TALEN-BASED AND CRISPR/CAS-BASED GENE EDITING FOR BRUTON'S TYROSINE KINASE
#1352MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#1353COMPOSITIONS AND METHODS FOR HIGHLY EFFICIENT GENETIC SCREENING USING BARCODED GUIDE RNA CONSTRUCTS
#1354Inhibition of unintended mutations in gene editing
#1355T cells with improved functionality
#1356CRISPR GUIDE-RNA EXPRESSION STRATEGIES FOR MULTIPLEX GENOME ENGINEERING
#1357Modified double-stranded RNA agents
#1358EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1359RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)
#1360CRISPR GENE EDITING FOR AUTOSOMAL DOMINANT DISEASES
#1361Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
#1362METHODS AND COMPOSITIONS FOR ENGINEERING CD4-DEFICIENT CAR T CELLS AND ANTI-CD4 CAR T CELLS AND USES THEREOF
#1363IMMUNOLOGICALLY COMPATIBLE CELLS, TISSUES, ORGANS, AND METHODS FOR TRANSPLANTATION FOR SILENCING, HUMANIZATION, AND PERSONALIZATION WITH MINIMIZED COLLATERAL GENOMIC DISRUPTIONS
#1364Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1365NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS
#1366Purification methods for guanine-rich oligonucleotides
#1367Optimized mRNA encoding CAS9 for use in LNPs
#1368SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
#1369COMPOSITIONS AND METHODS OF USE FOR SMALL-MOLECULE REGULATION OF CRISPR-CAS9 ACTIVITY USING RNA APTAMERS
#1370METHODS FOR DETERMINING INCREASED RISK OF CANCER DEVELOPMENT AND TREATING THE SAME
#1371SYSTEMS AND METHODS FOR NUCLEIC ACID PREPARATION
#1372Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
#1373Compositions and methods for delivery of biomacromolecule agents
#1374ARRAYED NUCLEIC ACID-GUIDED NUCLEASE OR NICKASE FUSION EDITING
#1375PEPTIDE BARCODES FOR CORRELATING NUCLEIC ACID-GUIDED NUCLEASE OR NICKASE FUSION EDITING AND PROTEIN TRANSLATION IN A POPULATION OF CELLS
#1376Expression of miRNAs in Placental Tissue
#1377Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1378OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
#1379METHODS FOR NOMINATION OF NUCLEASE ON-/OFF-TARGET EDITING LOCATIONS, DESIGNATED "CTL-seq" (CRISPR Tag Linear-seq)
#1380METHODS FOR STABLE GENOMIC INTEGRATION IN RECOMBINANT MICROORGANISMS
#1381SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
#1382Cure all for nucleic acid-guided cell editing in E. Coli
#1383NANOPORE MEMBRANE DEVICE AND METHODS OF USE THEREOF
#1384THERAPEUTIC USES OF GENE EDITED FIBROBLASTS
#1385CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE
#1386Lipids and compositions for the delivery of therapeutics
#1387Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
#1388Polyvinyl alcohol-degrading enzyme and process for producing the same
#1389IMPROVED VECTOR SYSTEMS FOR CAS PROTEIN AND SGRNA DELIVERY, AND USES THEREFOR
#1390DNA CUTTING MEANS BASED ON CAS9 PROTEIN FROM DEFLUVIIMONAS SP.
#1391MODIFIED Cas9 PROTEIN AND USE THEREOF
#1392METHODS OF IDENTIFYING IMMUNOMODULATORY GENES
#1393Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#1394PROTECTED GUIDE RNAS (PGRNAS)
#1395Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1396TARGETED ACTIVE GENE EDITING AGENT AND METHODS OF USE
#1397Gene editing
#1398RNA AND DNA BASE EDITING VIA ENGINEERED ADAR RECRUITMENT
#1399DUAL GUIDE RNA FOR CRISPR/CAS GENOME EDITING IN PLANTS CELLS
#1400COMPOSITIONS AND METHODS FOR MODULATING TRANSCRIPTIONAL ACTIVITY OF AMPLIFIED ONCOGENES CONTAINED ON EXTRACHROMOSOMAL DNA
#1401A METHOD FOR GENERATING RANDOM OLIGONUCLEOTIDES AND DETERMINING THEIR SEQUENCE
#1402Genome Editing by Guided Endonuclease and Single-stranded Oligonucleotide
#1403CELLS FOR THE PRODUCTION OF VIRUSES AND METHODS OF USING THE SAME
#1404IONIZABLE AMINE LIPIDS
#1405Use of aptamers in proteomics
#1406SYSTEMS AND METHODS FOR POLYNUCLEOTIDE SPATIAL ORGANIZATION
#1407MODIFIED DOUBLE-STRANDED RNA AGENTS
#1408TUNNELING NANOTUBE CELLS AND METHODS OF USE THEREOF FOR DELIVERY OF BIOMOLECULES
#1409PROGRAMMABLE NUCLEASES AND BASE EDITORS FOR MODIFYING NUCLEIC ACID DUPLEXES
#1410CRISPR/CPF1 SYSTEMS AND METHODS
#1411DNA cutting means based on Cas9 protein from biotechnologically significant bacterium Clostridium cellulolyticum
#1412PHARMACEUTICAL COMPOSITION THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN, PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B, AND SCREENING METHOD
#1413Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein
#1414Methods and compositions for determining pH
#1415NON-TOXIC CAS9 ENZYME AND APPLICATION THEREOF
#1416COMPOSITIONS AND METHODS FOR CONTROLLING INSECT PESTS
#1417ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#1418Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1419ARC-BASED CAPSIDS AND USES THEREOF
#1420GENE-EDITING SYSTEMS FOR EDITING A CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR (CFTR) GENE
#1421CRISPR-Cas12J effector polypeptides and methods of use thereof
#1422Compositions and methods for organ specific delivery of nucleic acids
#1423INHIBITOR OF NON-SPECIFIC BINDING OF NUCLEIC ACID, HYBRIDIZATION REAGENT AND NUCLEIC ACID HYBRIDIZATION METHOD
#1424CRISPR/CAS12F ENZYME AND SYSTEM
#1425COMPOSITIONS AND METHODS FOR OCHROBACTRUM-MEDIATED GENE EDITING
#1426COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#1427Selective Curbing of Unwanted RNA Editing (SECURE) DNA Base Editor Variants
#1428Compositions and methods for Editing Nucleic Acids in Cells Utilizing Oligonucleotides
#1429Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
#1430Nucleic acid nanocarrier drug and preparation method thereof
#1431Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1432Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1433Nucleic acid-guided nucleases
#1434Methods for genetic modification of plants
#1435Extended dicer substrate agents and methods for the specific inhibition of gene expression
#1436Methods of Manipulating the Fate of Cells
#1437ARTIFICIAL RNA-GUIDED SPLICING FACTORS
#1438NON-CANONICAL SWI/SNF COMPLEX AND USES THEREOF
#1439COMPOSITIONS AND METHODS FOR AIRWAY TISSUE REGENERATION
#1440Cell Line for Production of Marek's Disease Virus Vaccine and Methods of Making and Using the Same
#1441Methods and systems for monomer chain formation
#1442Synthetic immunomodulation with a CRISPR super-repressor in vivo
#1443Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
#1444MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCE
#1445TARGET VALIDATION AND PROFILING OF THE RNA TARGETS OF SMALL MOLECULES
#1446CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS
#1447Methods of use of CRISPR CPF1 hybrid DNA/RNA polynucleotides
#1448RNA MEDIATED GENE REGULATING METHODS
#1449METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS
#1450Compositions for genome editing
#1451Biodegradable lipids for delivery of nucleic acids
#1452SYSTEM AND METHOD FOR COLD ATMOSPHERIC PLASMA BASED T CELL THERAPY
#1453CRISPR/CAS-RELATED METHODS AND COMPOSITIONS TARGETING VIRUS GENOMES
#1454CRISPR/CAS Systems For Treatment of DMD
#1455Target sequence specific alteration technology using nucleotide target recognition
#1456Genome Editing by Directed Non-Homologous DNA Insertion Using a Retroviral Integrase-Cas9 Fusion Protein
#1457Soluble TNF Receptors and Their Use in Treatment of Disease
#1458COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS
#1459P-ethoxy nucleic acids for liposomal formulation
#1460METHODS AND COMPOSITIONS FOR EDITING RNAS
#1461CARGO LOADED EXTRACELLULAR VESICLES
#1462Bifunction chemical epigenetic modifiers and methods of use
#1463Engineered red blood cells having rare antigen phenotypes
#1464IN VITRO TOXICITY SCREENING ASSAY
#1465METHOD FOR FAST GENE EDITING AND CONSTRUCTING PRIMATE DISEASE MODEL
#1466GENERATION OF HERITABLY GENE-EDITED PLANTS WITHOUT TISSUE CULTURE
#1467GENE EDITING BASED CANCER TREATMENT
#1468THERAPEUTIC TARGETING OF MALIGNANT CELLS USING TUMOR MARKERS
#1469GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
#1470Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1471CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
#1472Modified AAV constructs and uses thereof
#1473Compositions and Methods for Inhibiting Intermediate Filament Tetramerization
#1474Compositions and Methods for Immunotherapy
#1475Single-stranded RNA-editing oligonucleotides
#1476ANTISENSE NUCLEIC ACIDS
#1477Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1478Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#1479EXTRACELLULAR VESICLES FOR TARGETED THERAPIES AGAINST MYELOID-DERIVED SUPPRESSOR CELLS
#1480HIV pre-immunization and immunotherapy
#1481Methods and compositions for nucleic acid and protein payload delivery
#1482METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN
#1483Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
#1484Method for gene editing
#1485CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
#1486Covalently fused viral coat proteins for the display of target molecules
#1487ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE
#1488CRISPR-Cas effector polypeptides and methods of use thereof
#1489Modified cells comprising CRISPR systems
#1490GENE TARGETS FOR T-CELL-BASED IMMUNOTHERAPY
#1491METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
#1492Nitrogen responsive transcription factors in plants
#1493STABLE TARGETED INTEGRATION
#1494Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf1
#1495CHIMERIC ANTIGEN RECEPTOR T CELLS DERIVED FROM IMMUNOENGINEERED PLURIPOTENT STEM CELLS
#1496METHODS FOR COMBINATORIAL SCREENING AND USE OF THERAPEUTIC TARGETS THEREOF
#1497Compositions of Asymmetric Interfering RNA and Uses Thereof
#1498NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS
#1499Treatment Of Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, And Liver Fibrosis
#1500Nuclease-mediated nucleic acid modification